Quantitative 18F-FDG PET-CT can assess presence and extent of interstitial lung disease in early severe diffuse cutaneous systemic sclerosis

Arthritis Res Ther. 2024 Dec 19;26(1):219. doi: 10.1186/s13075-024-03447-x.

Abstract

Background: This study aimed to assess the quantitative uptake of 18F-FDG PET-CT in the lungs of patients with early severe diffuse cutaneous systemic sclerosis (SSc) with and without interstitial lung disease (ILD), compared to controls. In patients with SSc-ILD, 18F-FDG uptake was correlated to high-resolution computed tomography (HRCT) and pulmonary function test (PFT) parameters.

Methods: A prospective, cross-sectional study was conducted, involving 15 patients with SSc-ILD, 5 patients with SSc without ILD, and 7 controls without SSc. 18F-FDG PET-CT scans were performed following standardized protocols, and quantitative analysis of tracer uptake was conducted in predefined lung regions. In addition, HRCT scans were evaluated for ILD-related radiologic abnormalities. Between-group differences were compared with non-parametric tests, while correlations with PFT parameters were analyzed using Spearman correlation coefficients.

Results: 18F-FDG uptake was mainly increased in the dorsobasal lung fields of patients with SSc-ILD compared to SSc without ILD and controls (p = 0.03 and p < 0.001, respectively). 18F-FDG uptake was higher in SSc patients with extensive ILD (≥ 20% vs < 20%, p = 0.04) and correlated with lower DLCO% (R = -0.59, p = 0.02). Ground-glass opacities, with or without reticulation, corresponded to increased 18F-FDG uptake.

Conclusions: 18F-FDG PET-CT can detect metabolic activity in the lungs of patients with early severe diffuse cutaneous SSc and ILD, correlating with higher ILD extent (≥ 20%) and lower DLCO%. These results suggest the potential utility of 18F-FDG PET-CT in the early detection of ILD (progression) and aiding in risk stratification.

Keywords: Imaging; Interstitial lung disease; Positron Emission Tomography; Systemic sclerosis.

MeSH terms

  • Adult
  • Aged
  • Cross-Sectional Studies
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Lung Diseases, Interstitial* / diagnostic imaging
  • Male
  • Middle Aged
  • Positron Emission Tomography Computed Tomography* / methods
  • Prospective Studies
  • Radiopharmaceuticals*
  • Respiratory Function Tests
  • Scleroderma, Diffuse / complications
  • Scleroderma, Diffuse / diagnostic imaging
  • Severity of Illness Index

Substances

  • Fluorodeoxyglucose F18
  • Radiopharmaceuticals